A comparative study of cefoselis and ceftazidime in chronic respiratory tract infections
Keywords:
cefoselis,
ceftazidime
1995 Volume 43 Issue 4 Pages 436-450
Details
1995 Volume 43 Issue 4 Pages 436-450
The clinical efficacy, safety and usefulness of cefoselis (FK037: FK), a new parenteral cephalosporin, were evaluated in chronic respiratory tract infection in a comparative study versus ceftazidime (CAZ). Each drug was administered by intravenous drip infusion at a dose of 1.0g (potency), twice daily for 14 days. The following results were obtained.
1. A total of 173 patients were enrolled in this study. Efficacy rates (“excellent” and “good” responses) were 90.5% (67/74) in the FK group and 90.0% (63/70) in the CAZ group.
2. Bacteriological effects (eradication rates) were 89.2% (33/37) in the FK groud and 94.3% (33/35) in the CAZ group.
3. Adverse reactions occurred in 6 of the 84 patients in the FK group and in 2 of the 79 patients in the CAZ group. The incidence of abnormal laboratory findings was 13.3% (11/84) in the FK group and 12.8% (10/78) in the CAZ group.
4. Usefulness rates (“very useful” and “useful” evaluations) were 84.0% (63/75) in the FK group and 87.1% (61/70) in the CAZ group.
